Background A perennial challenge in systemic cytotoxic cancer therapy is to eradicate primary tumors and metastatic disease while sparing normal tissue from off-target effects of chemotherapy. Anthracyclines such as doxorubicin are effective chemotherapeutic agents for which dosing is limited by development of cardiotoxicity. Our published evidence shows that targeting CD47 enhances radiation-induced growth delay of tumors while remarkably protecting soft tissues. The protection of cell viability observed with CD47 is mediated autonomously by activation of protective autophagy. However, whether CD47 protects cancer cells from cytotoxic chemotherapy is unknown. Methods We tested the effect of CD47 blockade on cancer cell survival using a 2-dimensional high-throughput cell proliferation assay in 4T1 breast cancer cell lines. To evaluate blockade of CD47 in combination with chemotherapy in vivo, we employed the 4T1 breast cancer model and examined tumor and cardiac tissue viability as well as autophagic flux. Results Our high-throughput screen revealed that blockade of CD47 does not interfere with the cytotoxic activity of anthracyclines against 4T1 breast cancer cells. Targeting CD47 enhanced the effect of doxorubicin chemotherapy in vivo by reducing tumor growth and metastatic spread by activation of an anti-tumor innate immune response. Moreover, systemic suppression of CD47 protected cardiac tissue viability and function in mice treated with doxorubicin. Conclusions Our experiments indicate that the protective effects observed with CD47 blockade are mediated through upregulation of autophagic flux. However, the absence of CD47 in did not elicit a protective effect in cancer cells, but it enhanced macrophage-mediated cancer cell cytolysis. Therefore, the differential responses observed with CD47 blockade are due to autonomous activation of protective autophagy in normal tissue and enhancement immune cytotoxicity against cancer cells.
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Background Due to advances in early cancer diagnosis and improvements in anti-neoplastic drugs, 20 million cancer survivors are expected by the year 2024 in the United States alone [1] . This is a positive milestone, but that success comes with serious adverse side effects causing secondary pathologies and limiting patient quality of life after anti-cancer therapy. Therefore, we need new drugs and combinatorial strategies that decrease or prevent off-target effects but do not interfere with the anti-cancer effects of cytotoxic therapy. Breast cancer patients, particularly those diagnosed with triple-negative breast cancer (TNBC), which respond only to systemic cytotoxic chemotherapy, are susceptible to off-target effects of chemotherapeutic agents including anthracycline-based drugs. We previously demonstrated that blockade of CD47 sensitizes tumors to death associated with local ionizing radiation, but protects bone marrow and soft tissues [2, 3] . A hepatocellular carcinoma xenograft model suggested similar additive effects of CD47 blockade with doxorubicin chemotherapy [4] , and another study found that doxorubicin treatment increases CD47 expression in TNBC [5] .
CD47 is a widely expressed receptor that controls cell fate via two major functions: (1) when it interacts with SIRPα on phagocytic cells, a "don't eat me" signal results that limits phagocytic activity. (2) On binding to TSP1, CD47 transduces signals that alter cellular calcium, cyclic nucleotide, integrin, growth factor signaling and control cell, viability and resistance to stress [6] . This latter function is fundamental to understanding why targeting CD47 could provide therapeutic benefits in disease such as cardiovascular diseases and cancer. This duality in survival effects makes CD47 an ideal target for cancer therapy. However, the mechanisms resulting in the selective protection of non-malignant tissues are not completely understood. Deficiency of CD47 protects T lymphocytes and primary endothelial cells from ionizing radiation through the activation of protective autophagy [3, 7] . Our group and others have attributed the anti-tumor effects of CD47 to enhancement of innate and adaptive immune system actions against the tumor [8, 9] . However, potential cell autonomous differences in the cytoprotective effects of CD47 blockade in normal versus cancer cells has not been examined, and is a critical question to address as agents targeting CD47 progress in human clinical trials.
We implemented a fully automated high-throughput screen using a 2-dimensional cell proliferation assay, where 1912 approved or experimental drugs were tested against 4T1 breast cancer cells with or without CD47 anti-sense morpholino treatment. The objective was to determine that blocking CD47 would not interfere with the oncologic efficacy of cytotoxic cancer therapy. Our data show that compounds in the anthracycline family fit this paradigm. Anthracyclines are used to treat several cancer types and are the standard approach for adjuvant treatment of breast cancer because they result in improved outcomes compared to other modalities [10] [11] [12] [13] . However, high cumulative doses of anthracyclines increase the risk of congestive heart failure by up to 26% [1] . Furthermore, although initial damage is acute, symptomatic manifestations occur long after chemotherapy.
In this study, we report that the cytoprotective effect of blocking CD47 extends to cardiac tissue. Our data show that blockade of CD47 in combination with anthracycline treatment reduced primary 4T1 tumor growth and prevented metastatic spread to the lungs. Moreover, cardiac tissue of mice administered with anthracycline alone showed increased cell death. However, heart tissue from mice administered the combination treatment showed protection from anthracycline-mediated death. Our data suggest that the protective effect of CD47 is due to an increase in autophagy, whereas the anti-tumor effects are associated to stimulation of macrophage-mediated cancer cell cytotoxicity. As shown previously, CD47 blockade increased protective autophagy hearts deficient in CD47 treated with anthracycline just as we had observed before in our previous studies in T cells [7] . The sensitization of tumors to anthracycline therapy was associated with increases in danger-associated proteins HMBG1 and Calreticulin. Overall, our data show that CD47 generally protects against chemotherapy-mediated cytotoxicity in normal cells, but this protective effect is lost in cancer cells and thus not compromising the oncologic efficacy of cytotoxic chemotherapy.
Methods

Cell culture
4T1 mouse breast cancer cells were a gift from Dr. Patricia Steeg [National Cancer Institute (NCI, National Institutes of Health (NIH) Bethesda, Maryland). H9C2 rat cardiac myoblast cells and Raw 264.7 murine macrophage cell lines were obtained from ATCC (CRL-1446, TIB-71), respectively. All cell lines were cultured in DMEM supplemented with 10% FBS penicillin/streptomycin, and glutamine kept at 37 °C and 5% CO 2 .
Quantitative high-throughput screen (qHTS)
4T1 breast cancer cells were seeded in 1536-well plates at 500 cells per well, in 50 µL of medium. Anti-sense CD47 morpholino (CD47M) was administered at a dose of 10 µM and was incubated in the flask for 48 h prior to the screen.
Compounds were added at multiple doses ranging from 0.8 nM to 46 µM. Cell viability was assessed after 48-h incubation at 37 °C by adding 30 µL of CellTiter-Glo reagent (Promega) and measuring luminescence (RLU) after a 15-m incubation at 25 °C, with ViewLux (PerkinElmer) [14] .
qHTS data analysis
Activity of the hits from the qHTS screen was analyzed as shown previously [14, 15] . Data were normalized and fitted to 4-parameter concentration response curves (CRC) using a gridbased algorithm. Each CRC was then assigned a heuristic curve response class. Curve classes of − 1.1, − 1.2, − 2.1, and − 2.2 are considered highest quality hits; classes of − 1.3, − 1.4, − 2.3, − 2.4, and − 3 are inconclusive hits; curve class values of 4 are inactive compounds. Additional parameters obtained from the qHTS fitting procedure and used for hit selection were the Maximum Response, which is the % activity at the maximum concentration of compound tested (46 µM) and the AC 50 , which is obtained from the curve fit. Differential activity of each compound between the wild type and knockdown CD47 conditions in each cell line was determined by calculating a difference in the maximum response or logAC 50 for each compound, between the two CD47 conditions, in each cell.
In vivo 4T1 orthotopic breast cancer model
Female Balb/c mice were injected with 4T1 cells (1 × 10 5 cells) into the mammary fat pad to induce tumor growth using a 26 gauge needle. Once tumors reached an average of 100 mm 3 mice (n = 8) were randomized, and one group received weekly IP injections of CD47M at a volume of 500 µL. Groups of control or morpholino-treated mice received 100 µL saline or doxorubicin (DOX) intravenously 48 h after each CD47 M injection. Tumor size was measured every third day using a caliper, and wet weight of the tumors was determined at the end of the study.
LC3 staining
H9C2 cardiac myoblast cells were transfected with a GFP-LC3 construct as shown previously [16] and treated 24 h after transfection. Images were sequentially acquired with Zeiss AIM software on a Zeiss LSM 510 confocal system and quantified blindly using Zen 2.3 sp1 software.
Histology
Tissue arrays from tumor tissues of human breast cancer patient sections analyzed in the Laboratory of Pathology National Cancer Institute, under approved protocol by the Institutional Review Board of the National Cancer Institute were immunostained as shown previously [9] using 1:250 B6H12 human anti-CD47antibody. Immunoreactivity was examined through light microscopy. Mouse lungs were harvested at the end of the study and subjected to Hematoxylin and Eosin stain to visualize tissue structure. Tumor lesions were quantified blindly by a pathologist under light microscopy.
Cytotoxicity assays
4T1 cells and H9C2 cells were plated at a density of 10,000 per well in a 96-well plate. 4T1 and H9C2 were transfected using 1 µM Endoporter and 10 µM CD47 morpholino. Twenty-four hours after transfection and plating, cells were treated with 1 µg/mL DOX and were incubated for 48 h. Cytotoxicity was measured by LDH release detected using a colorimetric activity assay (Invitrogen) and spectrophotometer (Benchmark plus microplate spectrophotometer, Bio-Rad). Cardiac function was assed by ultrasound using VEVO LAZR system in the M and B modes.
Real-time measurement of macrophage-mediated cytotoxicity
4T1 breast cancer target cells were seeded into 16-well plates. Cell growth was dynamically monitored using xCELLigence RTCA DP Real Time Cell Analyzer (ACEA Biosciences) for 24 h. RAW 264.7 macrophage cells were activated for 24 h at 37 °C with 10 ng/mL of LPS in complete medium and also used at an effector/target ration ratio of 5:1. After addition of effector cells, measurements were automatically collected by the analyzer. Cell-mediated cytolysis was calculated using xCELLigence software set to collect impendence data (reported as cell index).
Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM). Statistical differences were evaluated by Student's t test or one-way analysis of variance (ANOVA) followed by Tukey post hoc test. Animal studies were evaluated by repeated measures ANOVA followed by Tukey post hoc test. The criterion for statistical significance was set at p < 0.05.
Results
Screening of anti-sense CD47 morpholino activity in combination with cytotoxic drugs
High CD47 expression is associated with decreased survival in many cancers including breast [17] . Analysis of TCGA breast cancers classified based on RNAseq data using the established PAM50 panel of 50 genes [18, 19] shows that CD47 mRNA is elevated in basal-like breast cancers relative to HER2 and luminal A and B subtypes (Fig. 1a) . Our examination of human breast cancer tissue sections shows that CD47 expression is elevated in cancerous lesions of patients diagnosed with invasive breast cancer when compared to normal breast tissue ( Supplementary Fig. 1a) .
We have previously shown that blockade of CD47 enhances radiation tumor growth delay while protecting normal tissue from death from ionizing radiation [9, 20] . Thus, we wanted to know if CD47 blockade would also protect breast cancer cells from death associated with cytotoxic chemotherapy treatment and whether this additive activity extends to syngeneic tumors. Using a cell proliferation assay in a 1536-well microplate high-throughput screening format, we screened a comprehensive library of approved and late stage development oncology drugs in combination with a CD47 anti-sense morpholino to find combinatorial strategies that are more cytotoxic against breast cancer cells. We used the 4T1 breast cancer cell line to identify whether blockade of CD47 would protect cancer cells from cytotoxic chemotherapy. The endpoint for the high-throughput screen was cell viability assessed by measurement of cellular ATP using CellTiter Glo reagent. Compounds were tested at eleven doses ranging from 0.8 nM to 46 µM. Our data showed blocking CD47 decreased the anti-growth activity of doxorubicin (DOX) chemotherapy less than twofold (Fig. 1b) . Moreover, as observed in Fig. 1b -g, blockade of CD47 generally did not result in significant protection of breast cancer cells from cytotoxicity mediated by treatment with other members of the anthracycline family of drugs. In the 4T1 screen, 3 out of 6 drug treatments showed a modest increase in IC50 with CD47 blockade a (Fig. 1b , c, g; Table 1 ). Treatment with DOX showed a 1.4 increase in IC50 ( To corroborate that blockade of CD47 would not protect cells from anthracycline cytotoxicity, we examined cell cytotoxicity by measuring LDH release ( Fig. 1h ) from 4T1 cells treated with DOX in the presence or absence of antisense morpholino. DOX treatment increased breast cancer cell cytotoxicity in the presence or absence of CD47 blockade (*p < 0.05). A similar result was obtained when treating MDA-MB-231 cells ( Supplementary Fig. 1b ). Thus, our data indicate that blockade of CD47 does not directly limit the oncologic efficacy of anthracyclines.
Blockade of CD47 enhances anthracycline-mediated tumor cytotoxicity in a murine model of breast cancer
We chose DOX as the lead compound for our studies since it is widely used in the clinic particularly in patients presenting invasive breast cancer and triple-negative breast cancer patients [21] . Moreover, clinical use of anthracyclines is limited due to its off-target cytotoxic effects particularly in the cardiovascular system. We implanted 1 × 10 5 4T1 breast cancer cells in the fat pads of Balb/c mice and treated them with saline, DOX, CD47 morpholino (CD47M) or CD47M with DOX. Treatment with CD47M was done 2 days prior to each treatment with DOX and was repeated weekly for 30 days (Fig. 2a) . As observed in Fig. 2b , c, tumors of mice treated with saline tripled in size. DOX treatment caused the expected reduction in tumor volume and weight, but the combination of CD47 blockade and DOX further reduced tumor mass by 50% (Fig. 2b) . We confirmed knockdown of CD47 with anti-sense morpholino by western blot using the CD47 antibody miap301 (Supplementary Fig. 1c ). Therefore, blockade of CD47 enhances the effects of DOX to reduce breast tumor growth in a syngeneic tumor model, indicating that CD47 potentiates anthracycline-mediated breast tumor therapy.
The 4T1 model of breast cancer is known to develop lung metastasis after cells are injected orthotopically in the host mouse [22] . At the end of the study, we performed histopathological analysis of lung sections and observed that lungs of animals administered the combination treatment had a significant over 70% (*p < 0.01) reduction of metastatic lesions when compared to lungs of animals treated with saline (Fig. 2d , e, 4.2 ± 0.75 saline vs. 1.125 ± 0.6391 CD47M + Dox n = 8). DOX alone caused over 50% reduction in metastasis when compared with saline alone (4.2 ± 0.75 saline versus 2.000 ± 0.4629 doxorubicin alone, n = 8). CD47M monotherapy reduced metastasis by 46% when compared to saline alone. Notably only 25% of mice treated with the combination treatment developed metastatic lesions in the lungs when compared to 100% of mice treated with saline and 75% of both CD47M and DOX monotherapies (Fig. 2e) . This indicates that combination treatment of CD47M and DOX reduces metastatic spread, which suggests using this approach could improve clinical outcomes of breast cancer patients.
Blockade of CD47 enhances macrophage-mediated cytotoxicity of breast cancer cells
The increased efficacy of tumor ablation by combining DOX with CD47M in vivo contrasts with the weak cell autonomous effects observed in vitro in cancer cells and suggested that a non-cell autonomous immune mechanism is involved. Since blockade of CD47 enhances macrophagemediated cancer cell killing, we tested whether pretreatment with DOX modulated macrophage cytolytic capacity. We plated 4T1 breast cancer cells in 16-well plates and performed dynamic monitoring of RAW 264.7 mouse macrophage-mediated cytotoxicity of 4T1 breast cancer cells by measuring cell impedance using the ACEA xCelligence system (Fig. 3a) . The xCelligence system measures killing of adherent target tumor cells by a decrease in surface impedance, and is presented as a normalized cell index. Cell index is derived from the measured electrical impedance and is a quantitative measure of the number of viable adherent target cells in each well [23] . Therefore, a decreased cell index indicates loss of viable target tumor cells. This is an established quantitative real-time method for effector cell-mediated cytotoxicity against adherent target cells [9, 23] . We pretreated 4T1 breast cancer cells with anti-CD47 morpholino for 24 h and DOX for 4 h the following day then proceeded to remove the media and washed twice with new media and plated a suspension of macrophages at a 1:5 effector target ratio. As observed in Fig. 3a , DOX pretreatment reduced cell viability as expected from control (Fig. 3b, c) . Pretreatment with DOX enhanced macrophage-mediated cytotoxicity when compared to effector target pairs alone. Blockade of CD47 enhanced macrophage-mediated killing over untreated effector target pairs around 15 h (Fig. 3b) but no difference was observed at 24 h (Fig. 3c) . However, combination of CD47 blockade and DOX pretreatment significantly enhanced macrophage-mediated killing of cancer cells by reducing cell viability fivefold (*p < 0.001). This suggested that the enhancement observed in tumor killing in vivo by CD47 blockade is mediated in part by the macrophage-mediated cytotoxicity against cancer cells. To determine whether CD47 regulated macrophage infiltration in vivo we stained tumor tissue sections with a fluorescent antibody to CD68 and DAPI to denote nuclei (Fig. 3d) . Our data show that blocking CD47 in the presence or absence of DOX treatment increases macrophage infiltration by over 40% (*p < 0.05) when compared to DOX treatment alone (Fig. 3d, e) . DOX treatment showed an approximately 50% (*p < 0.05) decrease in macrophage infiltration when compared to saline-treated animals (Fig. 3d, e) . The increase in macrophage infiltration was significant with CD47 therapy alone when compared to saline-treated animals (Fig. 3d , e, *p < 0.05). Assessment of HMBG1, which facilitates macrophage-mediated cell clearance, was increased by over 10-fold in the combination treatment when compared to control (Fig. 3f) . Single DOX and CD47M treatments increased HMBG1 twofold (*p < 0.05) and threefold (*p < 0.05), respectively. Moreover, examination of calreticulin protein expression which facilitates the clearance of cancer cells by engaging its receptor on phagocytic cells [24] was increased by 30% (*p < 0.05) with CD47 treatment alone or and over 50% (*p < 0.05) with combination with DOX in tumor lysates from in vivo-treated mice (Fig. 3g, h ). This suggests that the enhanced reduction in tumor growth with the DOX and ANOVA, followed by Tukeys multiple comparison test). c Tumors were excised, and weights were recorded at the end of the study. d, e. After 30 days animals were euthanized, and lungs were excised. Tissue sections were paraffin embedded and stained with Hematoxylin and Eosin to determine tissue structure. Tumor lesions were counted by the pathologist under bright field microscopy N = 8, *p < 0.01 anti-sense CD47 treatment is mediated in part by activation of an immunogenic cell death pathway.
Blockade of CD47 prevents anthracycline-mediated cardiac cell and tissue toxicity
Anthracyclines are used to treat several cancer types and are the standard approach for adjuvant treatment of breast cancer because they result in improved outcomes compared to other modalities [10] [11] [12] [13] . However, high cumulative doses of anthracyclines compromise cardiovascular tissue causing the onset of congestive heart failure in patients [1] . To determine whether targeting CD47 may protect cardiac tissue from acute anthracycline associated death, we excised hearts of mice after one round of weekly DOX treatment in the presence or absence of prior treatment with CD47M. Sections were paraffin-embedded and subjected to TUNEL staining to detect cell death and were stained with wheat germ agglutinin to demark cardiomyocytes. Hearts of mice treated with DOX showed over a 15-fold increase in TUNEL staining when compared to saline-treated mice (Fig. 4a, b) . CD47 blockade in combination with DOX prevented the increase in TUNEL positive nuclei when compared to DOX alone (Fig. 4a, b) .
Since we have previously shown that blockade of CD47 increases autophagy as a mechanism to prevent death from ionizing radiation [16] we transfected H9C2 rat cardiac myoblasts with anti-sense morpholino to CD47 and treated with DOX to determine autophagy is regulated as a protective mechanism from cytotoxicity associated with DOX. 
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Transfection of GFP-LC3 construct into cardiac myoblast shows that LC3 puncta is increased by over 50% (*p < 0.001) with CD47 treatment in the presence or absence of DOX (Fig. 4c, d ) suggesting that autophagy is upregulated as a consequence of DOX treatment. Moreover, DOX treatment did not change accumulation of SQSTM1/p62 in cardiac cells when compared to control and showed a reduction in LC3 lipidation when compared to the combination treatment. (Fig. 4e-g ). Blockade of CD47 reduced the expression SQSTM1/p62 alone by 80% (*p < 0.01) (Fig. 4e, f and increased LC3 lipidation by 20% over control (Fig. 4e, g) ; however, combination treatment reduced SQSTM1/p62 degradation by almost 75% and increased LC3 lipidation threefold (*p < 0.01) (Fig. 4e-g ). These data indicate that the protective effect of CD47 blockade against DOX-associated cytotoxicity is associated with an increase in autophagic flux.
To determine whether autophagy is necessary for the protective effect against death associated with DOX, we cultured cardiac myoblasts in complete medium and treated with the autophagy inhibitor chloroquine (CQ). CQ elevates lysosomal pH, resulting in the inhibition autophagosome Fig. 4 Blockade of CD47 protects cardiac cells and tissue from doxorubicin mediated toxicity. A Hearts of mice were excised after doxorubicin treatment, sections were paraffin embedded and tissue was stained with TUNEL and WGA (red) to detect apoptotic cardiac cells and was quantified (B) under fluorescent microscopy (40×, Scale bar = 100 μm; 4 sections/animal n = 5, p < 0.05). H9C2 cardiac myoblasts were treated with CD47M and or DOX and transfected with LC3-GFP. LC3 puncta was determined by confocal microscopy (C) and quantified using ZEN 2.3 SP1 software (D). Autophagic flux was measured 24 h after DOX treatment in H9C2 cells by expression of SQSTM1/p62 and LC3 by Western Blot hybridization (E) and quantified by densitometry (F, G n = 4, *p < 0.05). H9C2 cardiac myoblast cells were plated and left untreated or administered CD47 Morpholino (CD47 M); 48 h after cells were treated with or without DOX in the presence absence of 25 μM chloroquine cells were incubated 24 h and LDH release was measured determine cell cytotoxicity n = 4, in triplicate, *p < 0.001 (H). ATG7 protein expression was assessed in H9C2 cells by western blot hybridization 24 h after DOX treatment (I) and was quantified (J) by densitometry (n = 4, *p < 0.05). H9C2 cardiac myoblast cells were plated and left untreated or transfected with CD47 M and/or ATG7 siRNA or control siRNA, 48 h after cells a group of cells was treated with DOX, 24 h later LDH release was measured to determine cell cytotoxicity, n = 4, *p < 0.001 (K) lysosome fusion [25] . Cardiac cells were treated with CQ 1 h prior to DOX treatment and cell viability was measured by LDH release. DOX increased cytotoxicity in cardiac myoblasts (Fig. 4h *p < 0.001) . However, CD47 blockade prevented the anthracycline-mediated cytotoxicity of cardiac myoblasts, demonstrating that the protective effect or CD47 blockade is cell autonomous. However, the protective effect of CD47 blockade from DOX associated cell cytotoxicity was lost following treatment with CQ. Thus, the observed chemo-protection from DOX treatment requires an autophagy mechanism.
We have previously demonstrated that the cytoprotection conferred by CD47 blockade in non-malignant cells is mediated by the upregulation of Autophagy Related Genes (ATG's) [7] . Our data show that targeting CD47 in combination with DOX increased ATG7 gene expression by over 50% (*p < 0.05) when compared to the rest of the treatment groups (Fig. 4i, j) . This serves as a further indication that autophagy is regulated as a protective mechanism with blockade of CD47. siRNA-mediated silencing of ATG7 did not affect cardiac cell cytotoxicity-associated DOX treatment. However, silencing of ATG7 reversed the protective effect of CD47 blockade against DOX cardiac cell cytotoxicity as it increased cytotoxicity over control and the combination of DOX and CD47M conditions (*p < 0.05, Fig. 4k ). This indicates that the cytoprotective effect of CD47 against DOX cardiac cell cytotoxicity is mediated by upregulation of the autophagy pathway.
Deficiency of CD47 preserves cardiac function after treatment with DOX
The heart has restricted regenerative capability; cumulative doses of anthracyclines surpass the threshold of damage that triggers ventricular remodeling, causing cardiac injury and limiting function [26] . Since fibrosis can accumulate in cardiac tissue, limiting contractility and function, we measured cardiac fibrosis as measured by picrosirius red staining Fig. 5 Deficiency of CD47 prevents DOX-associated cardiac fibrosis and preserves cardiovascular function. Hearts of mice were excised at the end of the tumor study and were paraffin embedded. Sections were stained with picrosirius red (a) and quantified using mantra inform pathology suite software (b) n = 5 *p < 0.05 (Scale bar 50 µm). Cardiovascular function was assessed using in vivo ultrasound with Vevo LAZR Photoacoustic Imaging System in WT and CD47−/− injected with I.V. with DOX (c-e) (Fig. 5a) . Examination of tissue sections showed a fivefold increase (*p < 0.01) in fibrosis after DOX treatment (Fig. 5b) over saline. However, treatment with CD47 prevented the increase in fibrosis after DOX treatment. Therefore, we predicted that CD47 blockade will improve cardiac function inhibiting collagen deposition.
To test this, we injected WT and Cd47−/− mice with DOX I.V. and measured cardiovascular function using in vivo ultrasound with the Vevo LAZR system. M-Mode tracing with in vivo ultrasound (Fig. 5c) shows no difference in cardiac function as measured by ejection fraction and fractional shortening between untreated WT and Cd47−/− mice (Fig. 5c top panels, d, e) . However, treatment with DOX significantly reduced the ejection fraction by almost 40% and fractional shortening by 50% (*p < 0.05). On the other hand, deficiency of CD47 preserved cardiac function after DOX treatment. These results indicate that CD47 blockade could be used as an adjuvant to prevent cardiac dysfunction in cancer patients receiving anthracycline chemotherapy and improve long-term cancer patient quality of life.
Discussion
One of the many challenges in cancer therapy is to maximally suppress tumor growth while preserving the integrity of normal tissue. We have previously demonstrated that blockade of CD47 enhances radiation growth delay in several syngeneic tumor models. In the same study, we showed that blockade of CD47 spared bone marrow and soft tissues from death caused by IR [2] . Further studies show that the protective effect was mediated by an increase in protective autophagy [3, 16] . A screen performed with 4T1 breast cancer cells demonstrated that blockade of CD47 did not interfere with the anti-cancer activity of the anthracycline family of compounds (Fig. 1b-g ). Since wehave shown previously in several models that blockade of CD47 is protective against cytotoxic stress,). Since we have shown previously in several models that blockade of CD47 is protective against cytotoxic stress, our goal was to rigorously show that the absence of CD47 would not interfere with the oncologic efficacy of chemotherapeutic compounds. Our results demonstrate that the anthracycline family of compounds fit these criteria. Our data confirm that DOX treatment is cytotoxic to cardiac myoblasts, but this toxicity is decreased by suppressing CD47, thus suggesting that targeting CD47 in combination with cytotoxic therapy may decrease the off-target effects of chemotherapy. Because elevated CD47 expression on tumor cells is associated with increased cancer progression by limiting innate and adaptive anti-tumor immunity, targeting this receptor may also enhance the anti-tumor effects of chemotherapy by protecting tumor-associated immune cells but not the tumor cells.
Clinical studies generally show that increased expression of CD47 is associated with poor prognosis in several types of cancer, including breast cancer [27, 28] . A study with over 700 patients demonstrated that patients with high expression of CD47 in the bone marrow cells had worse disease free survival (DFS) when compared to those with low levels of CD47 expression [29] . The expression profile also correlated with SIRPα expression. However, the same study showed that CD47 was an independent prognostic factor, and increased expression was associated with reduced overall survival and DFS [30] . Prior data using RNAseq show that CD47 expression is elevated in TNBC when compared to other breast cancer subtypes [31] . Consistent with previous publications, our new data indicate that expression of CD47 is elevated in basal-like breast cancer, and clinical samples of invasive breast cancer. This suggests a link between CD47 expression and poor prognosis of breast cancer patients.
Preclinical studies focus on how elevated CD47 expression allows cancer cells to escape innate immunosurveillance [32] [33] [34] . This reflects the normal homeostatic function of CD47 as a counter receptor for SIRPα (Fig. 3 ) that blocks phagocytosis [35] . On the other hand, CD47 also serves as a signaling receptor for the matricellular protein thrombospondin-1 [36, 37] . This interaction regulates responses to stress, tissue perfusion, and angiogenesis. Relevant to cancer therapy, the thrombospondin-1 peptide 4N1 binds to CD47, and downregulates caspase-3 protecting thyroid carcinoma cells against cytotoxic agents including DOX [38] . Thus, elevated expression of CD47 could cause resistance to chemotherapy, while also suggesting that inhibition of CD47 could be a pharmacological target to sensitize cancer cells to death.
Our published studies identified autophagy as a major target for CD47 signaling, to preserve cell and tissue viability during stress [3, 16] . Our data show that autophagic flux is increased in cardiac cells deficient of CD47 after DOX treatment. Upregulation of autophagy has been demonstrated to protect against DOX-associated cardiomyocyte cytotoxicity [39] . Moreover, DOX treatment of cardiomyocytes inhibits the autophagic flux, causing the accumulation of autophagosomes [40] . Consistent with these findings, DOX treatment causes accumulation of autophagosomes in cardiac myoblast evident by the clump pattern observed in Fig. 4c . which has been associated with accumulation of autophagosomes previously [41] . The inhibition of autophagic flux by DOX also explains why targeting with either CQ or knockdown with ATG7 (Fig. 4h, k) does not further sensitize cardiac cells to death, which could be expected in the treatment of cancer cells.
Autophagy signaling can have divergent effects on tumors. Inhibition of autophagy can sensitize cancer cells to chemotherapy [42] . However, the promotion of autophagy can also promote cancer cell death, particularly in in vivo models, whereas a recent study reported that autophagy inhibition increased the efficacy of inhibiting the CD47/ SIRPα interaction in a glioblastoma xenograft model [43] . However, whether CD47 blockade regulates autophagy in cancer cells is unknown. Our data show that blockade of CD47 in 4T1 and MDA-MB-231 breast cancer cells does not interfere with DOX associated cytotoxicity and thus not limiting its oncologic efficacy (Figs. 1b-h, Supplementary  Fig. 1a ). Our data (not shown) suggest that the canonical pathway of autophagy is not regulated in cancer cells by blockade of CD47. MDA-MB-231 cells express high levels of LC3-II [25] , suggesting that levels of autophagic flux may not play a cytoprotective role in these cancer cells.
Previous reports suggest that DOX treatment increases autophagy signaling [44, 45] . However, this may be context dependent; DOX may have different cell viability effects in various cancer or normal cell types [40] . Duality of autophagic signaling is well known [46] . Autophagy is known as program cell death III as formation of autophagosomes was associated with apoptosis [47] and autophagy may supplement metabolic signaling to promote survival induce drug resistance [46, 48] ; Therefore, these observations may rationalize the complexities of interpreting autophagy. Our goal here is to determine the regulation of autophagy at the time we observe cell death in the heart, which was 24 h after DOX treatment as shown by TUNEL staining (Fig. 4a, b) . While we cannot rule out that other genes of the autophagy pathway are not regulated by CD47 in cancer, the canonical protective autophagy pathways seem to be regulated differently between malignant and non-transformed cells.
The differential sensitivity of normal and cancer cells to CD47 blockade may be influenced by many factors including metabolism differences in tissues, levels of ROS, inflammatory environment among others. However, the sensitization of cancer cells to chemotherapy by CD47 blockade is due in part to the well-established effects of this receptor on antitumor immunosurveillance. Our data show that pretreatment with DOX and CD47 blockade significantly enhanced macrophage-mediated killing of breast cancer cells (Fig. 4a-c) . We have shown recently that sensitization of breast cancer cells to anti-estrogen therapy by targeting the Unfolded Protein Response (UPR) pathway is due in part to a reduction in CD47 expression and increase of the "eat me signals" calreticulin and high molecular group box 1 (HMGB1) [49, 50] . Therefore, regulation of these proteins in the absence of CD47 could account for the enhancement in the reduction of tumor growth over DOX alone.
DOX has been demonstrated to increase the release of "damage associated molecular patterns" (DAMPs) such as HMGB1, which stimulated immune cell clearance of B16 melanoma cells [51, 52] . Consistent with these results, we observed increased levels of HMBG1 in DOX-treated tumors when compared to saline-treated controls, which could account for the enhanced macrophage-mediated cytotoxicity observed with DOX-pretreatment in vitro. Furthermore, blockade of CD47 in combination with DOX resulted in a fivefold increase in HMBG1 over DOX alone, suggesting increased activation of an antitumor immune response over DOX consistent with the increased macrophage infiltration in the combination treatment (Fig. 3d) .
The clearance of cancer cells by CD47 blockade is limited by the expression of "eat me" signals such as calreticulin. Calreticulin facilitates clearance of cell by engaging its counter receptor LDL-receptor-related protein (LRP) on the phagocytic cell. Our data show that in vivo blockade of CD47 resulted in an increase in calreticulin that was not impaired with DOX treatment. Dendritic cell vaccination resulted in clearance of refractory lymphomas, which was associated with a decrease in CD47 and increase in calreticulin, HMGB1 [53] . This strategy increases immunogenicity of tumors. Our data show for the first time that targeting CD47 in combination with chemotherapy causes a similar regulation in breast cancer, indicating that the blockade of CD47 in combination with DOX results in activation of an immunogenic cells death pathway that results in enhanced tumor ablation in vivo. This combination treatment may also result in enhanced immunogenicity of breast cancer, which has been a limitation in observing meaningful benefits of immunotherapy in clinical treatment of breast cancer [54] . The immune microenvironment is complex and other immune cells contribute to anti-tumor immunosurveillance. The authors and others have shown that CD47 enhances adaptive immune responses against cancer cells [9, 55] , and therefore, the enhancement in tumor killing with CD47 blockade could be due to stimulation of other immune cell types.
CD47 was recently demonstrated to be under the transcriptional control of HIF-1 [56] . The low oxygen tension and the harsh conditions of the tumor microenvironment and expression levels of CD47 may be responsible for signaling effects in tumor and protection from cytotoxicity in tissues distant from the tumor. Cardiac tissue from our tumor bearing animals treated with DOX showed increased cell death, but this was inhibited when DOX was administered in combination with anti-sense CD47. The microenvironment in the heart is rich in oxygen and displays a different metabolic demand than the tumor. Therefore, the interplay of oxygen tension and metabolism may regulate CD47 expression as well as differential responses or normal and malignant tissues to cytotoxic therapy. Further studies are warranted to determine if hypoxia and metabolism may play a role in the autonomous regulation of these differential responses to CD47 targeting.
Conclusions
Overall our studies indicate that blockade of CD47 enhances anti-tumor responses to chemotherapy while preserving viability and function of the cardiovascular system. Since agents targeting CD47 are currently in clinical trials, these experiments suggest new combinatorial strategies to improve responses of patients with invasive and triple-negative breast cancer and the further examination of anti-CD47 therapy as an adjuvant to prevent secondary cardiovascular pathologies that arise as a consequence of chemotherapy in cancer survivors.
